EP0863704A4 - Stimulation de reponses immunes cellulaires par une imunisation genique ciblee utilisant un agent particulaire - Google Patents

Stimulation de reponses immunes cellulaires par une imunisation genique ciblee utilisant un agent particulaire

Info

Publication number
EP0863704A4
EP0863704A4 EP96933987A EP96933987A EP0863704A4 EP 0863704 A4 EP0863704 A4 EP 0863704A4 EP 96933987 A EP96933987 A EP 96933987A EP 96933987 A EP96933987 A EP 96933987A EP 0863704 A4 EP0863704 A4 EP 0863704A4
Authority
EP
European Patent Office
Prior art keywords
immuned
stimulation
cell
immune response
genetic immunization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96933987A
Other languages
German (de)
English (en)
Other versions
EP0863704A1 (fr
Inventor
Louis D Falo Jr
Kenneth L Rock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
University of Pittsburgh
Original Assignee
Dana Farber Cancer Institute Inc
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc, University of Pittsburgh filed Critical Dana Farber Cancer Institute Inc
Publication of EP0863704A1 publication Critical patent/EP0863704A1/fr
Publication of EP0863704A4 publication Critical patent/EP0863704A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/00119Melanoma antigens
    • A61K39/001192Glycoprotein 100 [Gp100]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/711Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001102Receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001102Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103Receptors for growth factors
    • A61K39/001106Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001148Regulators of development
    • A61K39/00115Apoptosis related proteins, e.g. survivin or livin
    • A61K39/001151Apoptosis related proteins, e.g. survivin or livin p53
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/00118Cancer antigens from embryonic or fetal origin
    • A61K39/001182Carcinoembryonic antigen [CEA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001184Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186MAGE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/00119Melanoma antigens
    • A61K39/001191Melan-A/MART
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/19Dendritic cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/20Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24Antigen-presenting cells [APC]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/42Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
EP96933987A 1995-09-28 1996-09-27 Stimulation de reponses immunes cellulaires par une imunisation genique ciblee utilisant un agent particulaire Withdrawn EP0863704A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53555695A 1995-09-28 1995-09-28
PCT/US1996/015728 WO1997011605A1 (fr) 1995-09-28 1996-09-27 Stimulation de reponses immunes cellulaires par une imunisation genique ciblee utilisant un agent particulaire
US535556 2000-03-27

Publications (2)

Publication Number Publication Date
EP0863704A1 EP0863704A1 (fr) 1998-09-16
EP0863704A4 true EP0863704A4 (fr) 2003-09-10

Family

ID=24134735

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96933987A Withdrawn EP0863704A4 (fr) 1995-09-28 1996-09-27 Stimulation de reponses immunes cellulaires par une imunisation genique ciblee utilisant un agent particulaire

Country Status (15)

Country Link
EP (1) EP0863704A4 (fr)
JP (1) JPH11512724A (fr)
KR (1) KR19990063672A (fr)
CN (1) CN1201369A (fr)
AU (1) AU716497B2 (fr)
BG (1) BG102355A (fr)
CA (1) CA2233278A1 (fr)
CZ (1) CZ92998A3 (fr)
HU (1) HUP9802651A3 (fr)
NO (1) NO981386L (fr)
NZ (1) NZ319891A (fr)
PL (1) PL325953A1 (fr)
SK (1) SK40198A3 (fr)
TR (1) TR199800573T2 (fr)
WO (1) WO1997011605A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997044446A1 (fr) * 1996-05-24 1997-11-27 University Of Maryland At Baltimore Vaccins d'adn induisant une immunoreaction des muqueuses
TW570803B (en) * 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6287569B1 (en) * 1997-04-10 2001-09-11 The Regents Of The University Of California Vaccines with enhanced intracellular processing
AU3291099A (en) * 1998-02-11 1999-08-30 Maxygen, Inc. Genetic vaccine vector engineering
US7390619B1 (en) 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
AU2487300A (en) 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
JP2002542264A (ja) * 1999-04-21 2002-12-10 パウダージェクト ヴァクシンズ,インコーポレイテッド 核酸による免疫化
JP4430868B2 (ja) 2001-03-30 2010-03-10 ジーエイチシー リサーチ ディベロップメント コーポレイション 単球に特異的な粒子性送達媒体
EP1411770A4 (fr) 2001-07-05 2006-05-10 Chiron Corp Polynucleotides codant des polypeptides de type c du vih antigeniques, polypeptides et leurs utilisations
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
US11529414B2 (en) 2020-06-23 2022-12-20 Orbis Health Solutions, Llc Viral vaccines for in vivo expression of a nucleic acid encoding an immunogenic peptide and methods of using the same

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 15 April 1995 (1995-04-15), ZAROZINSKI C C ET AL: "Protective CTL-dependent immunity and enhanced immunopathology in mice immunized by particle bombardment with DNA encoding an internal virion protein.", XP002238694, Database accession no. NLM7706740 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 4 September 1995 (1995-09-04), FOMSGAARD A: "[Genetic immunization--"the biological equivalent of cold fusion"?]", XP002238693, Database accession no. NLM7676526 *
FYNAN E F ET AL: "DNA VACCINES: PROTECTIVE IMMUNIZATIONS BY PARENTERAL, MUCOSAL, AND GENE-GUN INOCULATIONS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 90, 1 December 1993 (1993-12-01), pages 11478 - 11482, XP000770731, ISSN: 0027-8424 *
HEYDENBURG FULLER D ET AL: "A QUALITATIVE PROGRESSION IN HIV TYPE 1 GLYCOPROTEIN 120-SPECIFIC CYTOTOXIC CELLULAR AND HUMORAL IMMUNE RESPONSES IN MICE RECEIVING ADNA-BASED GLYCOPROTEIN 120 VACCINE", AIDS RESEARCH AND HUMAN RETROVIRUSES, NEW YORK, NY, US, vol. 10, no. 11, 1 November 1994 (1994-11-01), pages 1433 - 1441, XP000572444, ISSN: 0889-2229 *
JOURNAL OF IMMUNOLOGY (BALTIMORE, MD.: 1950) UNITED STATES 15 APR 1995, vol. 154, no. 8, 15 April 1995 (1995-04-15), pages 4010 - 4017, ISSN: 0022-1767 *
LAI W C: "PROTECTION AGAINST MYCOPLASMA PULMONIS INFECTION BY GENETIC VACCINATION", DNA AND CELL BIOLOGY, NEW YORK, NY, US, vol. 14, no. 7, 1 July 1995 (1995-07-01), pages 643 - 651, XP000575588, ISSN: 1044-5498 *
See also references of WO9711605A1 *
UGESKRIFT FOR LAEGER. DENMARK 4 SEP 1995, vol. 157, no. 36, 4 September 1995 (1995-09-04), pages 4932 - 4936, ISSN: 0041-5782 *

Also Published As

Publication number Publication date
HUP9802651A2 (hu) 1999-02-01
AU7251596A (en) 1997-04-17
CN1201369A (zh) 1998-12-09
SK40198A3 (en) 1998-11-04
WO1997011605A1 (fr) 1997-04-03
NZ319891A (en) 1999-01-28
CA2233278A1 (fr) 1997-04-03
NO981386L (no) 1998-05-28
HUP9802651A3 (en) 2001-08-28
EP0863704A1 (fr) 1998-09-16
AU716497B2 (en) 2000-02-24
CZ92998A3 (cs) 1998-09-16
NO981386D0 (no) 1998-03-26
TR199800573T2 (xx) 1998-07-21
JPH11512724A (ja) 1999-11-02
PL325953A1 (en) 1998-08-17
BG102355A (bg) 1999-04-30
KR19990063672A (ko) 1999-07-26

Similar Documents

Publication Publication Date Title
DE69633333D1 (de) Diphosphonatderivate von therapeutischen substanzen
DE69638248D1 (de) Nachweis von DNS-Sequenz Variationen
DE69627895D1 (de) Herstellungsverfahren von mikroprismenmatrixen
DE69608448D1 (de) Reduktion des biobewuchses
EP0863704A4 (fr) Stimulation de reponses immunes cellulaires par une imunisation genique ciblee utilisant un agent particulaire
ATE198190T1 (de) Modulatoren von durch aminosäuren anregbare rezeptoren
DE69602011D1 (de) Implantierbare stimulationselektroden
NO974089L (no) Stimulering av meiose
EP0817798A4 (fr) Sequences nucleotidiques et proteiques de genes lats et procedes les utilisant
FI973484L (fi) Menetelmä immuunivasteen stimuloimiseksi
DE69628195D1 (de) Verwendung von xyloglucanendotransglycosylase
IT1285405B1 (it) Modificazione di farmaci polipeptidici per accrescere il flusso per elettrotrasporto.
DE69622472D1 (de) Behandlung von Krankheiten durch Induktion von BEF-1 Transkriptionsfaktor
FI952176A7 (fi) Suovan neutralointi
DE69608454D1 (de) Simulation von atmosphärischen effekten
ATA136995A (de) Abreicherung von 7-adca in 3-vinyl-aca
ITRM960887A0 (it) Composizioni di esteri vinilici di novolacca
DE69603578D1 (de) Synthese von tetrafluorethylen
DE69634725D1 (de) Verbesserte haftung von fluorpolymeren
DE69605708D1 (de) Reinigung von Pentafluorethan
NO980862L (no) Zwitterionformer av trovafloxacin
DE69610739D1 (de) Umwandlung von substituierten 8-Chlorochinolinen in substituierte 8-Hydroxychinoline
DE59506059D1 (de) Halterung fur die biegemomentfreie lagerung von glastafeln
HK1015223A (en) Stimulation of cell-mediated immune responses by targeted particulate genetic immunization
KR970011240U (ko) 바란스 블럭의 다기능 도그

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980324

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: LT PAYMENT 980324;LV PAYMENT 980324;SI PAYMENT 980324

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DANA FARBER CANCER INSTITUTE

Owner name: UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DANA FARBER CANCER INSTITUTE

Owner name: DANA FARBER CANCER INSTITUTE, INC.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DANA FARBER CANCER INSTITUTE, INC.

Owner name: UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTE

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 47/02 B

Ipc: 7A 61K 48/00 B

Ipc: 7A 61K 39/00 A

A4 Supplementary search report drawn up and despatched

Effective date: 20030723

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20031103

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1015223

Country of ref document: HK